Who are Drug: cimetidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Axid Ar, Zantac, Histalog, Tagamet, Bentyl, Rosuvastatin-ranitidine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drug-cimetidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Drug: cimetidine — Competitive Intelligence Brief

Drug: cimetidine (Drug: cimetidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H2 receptor antagonist. Area: Gastroenterology.

marketed H2 receptor antagonist Histamine H2 receptor Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Drug: cimetidine (Drug: cimetidine) — University of Maryland, Baltimore. Cimetidine blocks histamine H2 receptors on gastric parietal cells to reduce stomach acid production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Drug: cimetidine TARGET	Drug: cimetidine	University of Maryland, Baltimore	marketed	H2 receptor antagonist	Histamine H2 receptor
Axid Ar	NIZATIDINE		marketed	Histamine-2 Receptor Antagonist [EPC]	Histamine H2 receptor	1988-01-01
Zantac	ranitidine	GSK (originally Glaxo)	marketed	H2 receptor antagonist	Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor	1983-06-01
Histalog	BETAZOLE		marketed	betazole	Histamine H2 receptor	1982-01-01
Tagamet	CIMETIDINE		marketed	Histamine-2 Receptor Antagonist [EPC]	Histamine H2 receptor	1977-01-01
Bentyl	dicycloverine	Forest Labs Inc	marketed	Anticholinergic	Histamine H2 receptor	1950-01-01
Rosuvastatin-ranitidine	Rosuvastatin-ranitidine	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist	HMG-CoA reductase (rosuvastatin component); Histamine H2 receptor (ranitidine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H2 receptor antagonist class)

GSK (originally Glaxo) · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
University of Maryland, Baltimore · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Drug: cimetidine — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-cimetidine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab